个人简介:
周倩博士，硕士生导师，本科毕业于兰州大学，随后被保送到武汉大学进行硕博连读，博士毕业后前往法国居里研究所开展博士后研究。于2018年1月加入暨南大学生命科学技术学院开展教学科研工作。目前从事肺癌早期诊断、癌变机理及相关治疗的研究。周倩博士在国内外权威刊物如《Cell Host Microbe》、《EMBO Molecular Medicine》、《Cell Research》、《PNAS》、《Theranostics》、《Nature Communications》等发表SCI论文20余篇，以第一或通讯作者（包括共同）发表论文11篇，影响因子大于10的论文8篇；主持国家级项目2项（青年基金1项，面上基金1项）、省部级基金等6项（广东省青年人才提升项目1项，面上基金1项，广州市基础研究及市校联合基金各1项，其它基金2项），法国FRM基金，横向项目2项，参与国家重点研发计划等项目2项；授权发明专利2项；获批2023年“暨南杰青”。讲授生物化学实验，参与讲授肿瘤分子生物学，功能蛋白质研究等课程。担任2020级生物技术班班主任，《生物医学科学与工程》期刊编委，“肿瘤分子生物学”教育部重点实验室青年骨干，任IJMS, Cell cycle等多个国际期刊审稿人，教育部学位论文评审专家，广东省自然科学基金评审专家等。
职称：副研究员
学习经历
1. 2005-2009：兰州大学，生物技术专业（国家奖学金等）
2. 2009-2014：武汉大学，硕博连读，导师：舒红兵 教授（学术创新奖一等奖等）
工作经历
1. 2015-2018：法国居里研究所，博士后，合作导师：Olivier Lantz教授
2. 2018-至今：暨南大学生命科学技术学院，副研究员，硕士生导师
荣誉奖励
暨南杰青，湖北省优秀博士论文
研究方向：
1. 肺癌精准治疗的分子基础：通过全基因组规模的筛选，鉴定参与肺癌的抑癌基因以及癌基因，确定新型的肺癌抑癌基因和癌基因的生物学功能，解析其发挥功能的生物学机制，并研究相应肺癌的精准治疗策略。
2. 聚焦肺癌免疫微环境的调控及药物研发：针对肺癌免疫微环境，构建筛选细胞模型及免疫功能正常的转基因肺癌小鼠模型，筛选并改进设计新型小分子及生物大分子抑制剂，测试其针对特定肺癌的疗效，并解析其调控肺癌免疫微环境的分子机制。
主要论文：
1. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. Qian Zhou*#, Jinxia Liang*, Tong Yang, Jin Liu1, Bo Li, Yingchang Li, Zhenzhen Fan, Weida Wang, Wensheng Chen, Sujing Yuan, Meng Xu, Qigui Xu, Zhidong Luan, Zhongjun Xia, Penghui Zhou, Yadong Huang, Liang Chen#. EMBO Molecular Medicine. 2022 Jan 11; 14(1): e14502.
2. Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. Qian Zhou*#, Wensheng Chen*, Zhenzhen Fan*, Zhipeng Chen*, Jinxia Liang*, Guandi Zeng, Lu Liu, Wanting Liu, Tong Yang, Xin Cao, Biao Yu, Meng Xu, Ye-Guang Chen# and Liang Chen#. Theranostics. 2021; 11(13): 6592–6606.
3. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non–small cell lung cancer. Bo Li*, Tong Yang*, Jin Liu, Xixi Yu, Xinying Li, Fei Qin, Jiefei Zheng, Jinxia Liang, Youyan Zeng, Zhenhua Zhou, Lu Liu, Bin Zhang, Weiwei Yao, Zhuo Feng, Guandi Zeng, Qian Zhou#, Liang Chen#, Acta Biomaterialia. 2023 Apr 15;161:184-200.
4. In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer. Lu Liu*, Yuxi Lei*, Wensheng Chen*, Qian Zhou*#, Zongyao Zheng, Guandi Zeng, Wanting Liu, Pengju Feng, Zhiyi Zhang, Lei Yu#, Liang Chen#, Cell Bioscience. 2022 Dec 1;12(1):193.
5. A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients. Feng Lu*, Qian Zhou*#, Lu Liu*, Guandi Zeng, Weimin Ci, Wanting Liu, Gong Zhang, Zhiyi Zhang, Peng Wang, Aiqun Zhang, Yunfei Gao#, Lei Yu#, Qingyu He#, and Liang Chen#, Theranostics. 2020; 10(2): 484–497.
6. IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function. Jinxia Liang＃, Feng Lu＃, Bo Li#, Lu Liu, Guandi Zeng, Qian Zhou#, Liang Chen#, Cell Cycle. 2019 Dec;18(23):3300-3312.
7. Discovery of Novel Inhibitor for WNT/b-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. Bo Li*, Jinxia Liang*, Feng Lu*, Jindao Zhang, Yinxing Ma, Pen Liu, Qin Wang, Qian Zhou#, Liang Chen#，Molecules. 2020 Apr 6;25(7):1680.
8. Mitochondria-targeted magnetic gold nanoheterostructure for multi-modal imaging guided photothermal and photodynamic therapy of triple-negative breast cancer. Bo Li*, Qian Zhou*, Haiyang Wang*, Yongchao Zha*, Peilian Zheng, Tong Yang, Dong Ma#, Lin Qiu, Ximing Xu, Ye Hu, Anna Roig, Siming Yu#, Wei Xue#，Chemical Engineering Journal， Volume 403, 1 January 2021, 126364
9. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-kB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Zhipeng Chen*, Zhenzhen Fan*, Xiaowei Dou*, Qian Zhou*, Guandi Zeng*, Lu Liu, Wensheng Chen, Ruirui Lan, Wanting Liu, Guoqing Ru#, Lei Yu#, Qing-Yu He#, Liang Chen#，Theranostics. 2020 Sep 16;10(25):11520-11534.
10. The ER-associated protein ZDHHC1 is a positive regulator of DNA virus-triggered, MITA/STING-dependent innate immune signaling. Qian Zhou, Heng Lin, Suyun Wang, Shuai Wang, Yong Ran, Ying Liu, Wen Ye, Xiaozhe Xiong, Bo Zhong, Hong-Bing Shu#, Yan-Yi Wang#. Cell Host Microbe. 2014 Oct 8;16(4):450-61
11. Crystal structure of ISG54 reveals a novel RNA binding structure and potential functional mechanisms. Zhenlin Yang*, Huanhuan Liang*, Qian Zhou*, Ying Li, Haiwei Chen, Wen Ye, Danying Chen, Joy Fleming, Hongbing Shu, Yingfang Liu，Cell Research. 2012 Sep;22(9):1328-38.
12. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. Zhenzhen Fan, Yahui Tian, Zhipeng Chen, Lu Liu, Qian Zhou, Jingjing He, James Coleman, Changjiang Dong, Nan Li, Junqi Huang, Chenqi Xu, Zhimin Zhang, Song Gao, Penghui Zhou, Ke Ding, Liang Chen. EMBO Molecular Medicine. 2020 Jun 8;12(6):e11571.
13. Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Lei Gao, Yong Hu, Yahui Tian, Zhenzhen Fan, Kun Wang, Hongdan Li, Qian Zhou, Guandi Zeng, Xin Hu, Lei Yu, Shiyu Zhou, Xinyuan Tong, Hsinyi Huang, Haiquan Chen, Qingsong Liu, Wanting Liu, Gong Zhang, Musheng Zeng, Guangbiao Zhou, Qingyu He, Hongbin Ji, Liang Chen. Nature Communications 2019 Apr 10;10(1):1665.
14. ZDHHC11 modulates innate immune response to DNA virus by mediating MITA-IRF3 association. Ying Liu, Qian Zhou, Li Zhong, Heng Lin, Ming-Ming Hu, Yan Zhou, Hong-Bing Shu & Shu Li. Cellular & Molecular Immunology volume 15, pages907–916 (2018).
15. MARCH3 attenuates IL-1β-triggered inflammation by mediating K48-linked polyubiquitination and degradation of IL-1RI. Heng Lin, Deng Gao, Ming-Ming Hu, Man Zhang, Xiao-Xia Wu, Lu Feng, Wen-Hua Xu, Qing Yang, Xuan Zhong, Jin Wei, Zhi-Sheng Xu, Hong-Xia Zhang, Ze-Min Song, Qian Zhou, Wen Ye, Ying Liu, Shu Li, Hong-Bing Shu. Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12483-12488.
16. TRIM8 Negatively Regulates TLR3/4-Mediated Innate Immune Response by Blocking TRIF-TBK1 Interaction. Wen Ye, Ming-Ming Hu, Cao-Qi Lei, Qian Zhou, Heng Lin, Ming-Shun Sun, Hong-Bing Shu. J Immunol. 2017 Sep 1;199(5):1856-1864.
17. MHC class I-related molecule, MR1, and mucosal-associated invariant T cells. (2016). Katarzyna Franciszkiewicz, Marion Salou, Francois Legoux, Qian Zhou, Yue Cui, Stéphanie Bessoles, Olivier Lantz. Immunological reviews. 20 June 2016.
18. LSm14A is a processing body-associated sensor of viral nucleic acids that initiates cellular antiviral response in the early phase of viral infection. Ying Li, Rui Chen, Qian Zhou, Zhisheng Xu, Chao Li, Shuai Wang, Aiping Mao, Xiaodong Zhang, Weiwu He, Hong-Bing Shu. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11770-5.
19. Heat shock cognate 71 (HSC71) regulates cellular antiviral response by impairing formation of VISA aggregates. Zhigang Liu, Shu-Wen Wu, Cao-Qi Lei, Qian Zhou, Shu Li, Hong-Bing Shu, Yan-Yi Wang. Protein Cell. 2013 May;4(5):373-82.
20. The E3 ubiquitin ligase MARCH8 negatively regulates IL-1beta-induced NF-kappaB activation by targeting the IL1RAP coreceptor for ubiquitination and degradation. Rui Chen, Mi Li, Yu Zhang, Qian Zhou, Hong-Bing Shu. Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14128-33.
21. SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. Yong Ran, Tian-Tian Liu, Qian Zhou, Shu Li, Ai-Ping Mao, Ying Li, Li-Juan Liu, Jin-Ke Cheng, Hong-Bing Shu. J Mol Cell Biol. 2011 Oct;3(5):283-92.
承担课题：
1. 国家自然科学基金-面上基金，50万元，2024-2027，主持
2. 国家自然科学基金-青年基金，27万元，2018~2021，主持
3. 法国FRM基金，10万欧元，2016~2017，主持
4. 广东省自然科学基金-青年提升项目，30万，2024-2026，主持
5. 广东省自然科学基金-面上项目，10万元，2021~2023，主持
6. 广州市自然科学基金-市校（院）企联合资助，20万元，2024-2026，主持
7. 广州市基础与应用基础项目，5万元，2021~2023，主持
8. 暨南大学科研培育基金，15万元，2018~2020，主持
9. 暨南大学高层次人才科研启动基金，20万元，2018~2021，主持
10. 正大天晴药业股份有限公司-横向项目，21.3万元，2021~2022，主持
11. 南京红云科技有限公司-横向项目，20万元，2021-01~2021-12，主持
12. 国家重点研发计划，1018万，2023-2027，核心骨干
13. 中央高校基本科研业务费（创新基金），15万，2019-2021，核心骨干
授权专利：
1. 用于治疗K+M-肺癌的联合药物，202110373242.5，第一发明人
2. 用于治疗肿瘤的联合药物，ZL202111125450.X，第二发明人
讲授课程：
生物化学实验，肿瘤分子生物学，功能蛋白研究
电子邮箱：zhouqian@jnu.edu.cn
办公电话：020-8522623
办公地址：广东省广州市天河区第二理工楼644